Wegovy

Wegovy (semaglutide 2.4mg) is the FDA-approved weight management version of semaglutide. It works identically to Ozempic - as a GLP-1 receptor agonist that reduces appetite and slows digestion - but is dosed higher (2.4mg vs 2mg max for Ozempic) and was specifically studied in large-scale weight loss clinical trials.

The STEP 1 trial showed patients on Wegovy lost an average of 14.9% of body weight (about 33 lbs) over 68 weeks. In the STEP 3 trial, which combined Wegovy with intensive behavioral therapy, average weight loss reached 16%. About one-third of participants lost 20% or more of their body weight.

Wegovy has broader insurance coverage for weight loss than Ozempic since it carries the FDA weight management indication. However, many plans still exclude weight loss medications. Coverage often requires BMI 30+ or BMI 27+ with comorbidities, plus prior authorization. Some employer plans have added GLP-1 coverage due to demand. Without insurance, Wegovy costs approximately $1,300-$1,700/month.

Compounded semaglutide can be dosed at the same 2.4mg level as Wegovy at a fraction of the cost. The trade-off is that compounded versions lack the specific FDA approval and standardized manufacturing of the brand-name product. Many providers offer both options and let patients choose based on their budget and preferences.